The risk of developing severe symptoms caused by SARS-CoV2 infection in patients (pts) with cutaneous mastocytosis (CM), or indolent systemic mastocytosis (ISM) is like that of healthy people. Unfortunately, the risk may increase in pts with aggressive systemic mastocytosis (ASM), or mastocytosis associated to a hematologic neoplasm (SM-AHN). SARS-CoV2 vaccination reduces the risk of a potentially fatal infection. Considering the increased risk of allergic reactions, it is crucial for these pts to be safely vaccinated. The incidence of vaccine-related anaphylaxis has been reported to be 5 times higher for mRNA vaccines than others. The Italian Ministry of Health (MH) suggests mRNA vaccines for frail individuals. In pts with mastocytosis, it recommended prophylaxis with antihistamines from the day prior to the vaccination to 5 days after, and an observation of 60 min after the vaccination. The administration of the vaccine in a hospital setting was recommended in those with a history of anaphylaxis episodes. In our hospital a vaccination campaign for frail pts in 2 phases was organized.

P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE / Filipponi, V.; Palumbo, Giovanna; Ribersani, M.; Moleti, M. L.; Angi, A.; Molinari, M. C.; Maglione, R.; Giona, F.. - In: HEMASPHERE. - ISSN 2572-9241. - 6:(2022), pp. 1461-1462. [10.1097/01.HS9.0000849176.79030.e3]

P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE

Filipponi, V.;Palumbo, Giovanna;Ribersani, M.;Moleti, M. L.;Angi, A.;Molinari, M. C.;Maglione, R.;Giona, F.
2022

Abstract

The risk of developing severe symptoms caused by SARS-CoV2 infection in patients (pts) with cutaneous mastocytosis (CM), or indolent systemic mastocytosis (ISM) is like that of healthy people. Unfortunately, the risk may increase in pts with aggressive systemic mastocytosis (ASM), or mastocytosis associated to a hematologic neoplasm (SM-AHN). SARS-CoV2 vaccination reduces the risk of a potentially fatal infection. Considering the increased risk of allergic reactions, it is crucial for these pts to be safely vaccinated. The incidence of vaccine-related anaphylaxis has been reported to be 5 times higher for mRNA vaccines than others. The Italian Ministry of Health (MH) suggests mRNA vaccines for frail individuals. In pts with mastocytosis, it recommended prophylaxis with antihistamines from the day prior to the vaccination to 5 days after, and an observation of 60 min after the vaccination. The administration of the vaccine in a hospital setting was recommended in those with a history of anaphylaxis episodes. In our hospital a vaccination campaign for frail pts in 2 phases was organized.
2022
SARS-CoV2, mastocytosis
01 Pubblicazione su rivista::01a Articolo in rivista
P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE / Filipponi, V.; Palumbo, Giovanna; Ribersani, M.; Moleti, M. L.; Angi, A.; Molinari, M. C.; Maglione, R.; Giona, F.. - In: HEMASPHERE. - ISSN 2572-9241. - 6:(2022), pp. 1461-1462. [10.1097/01.HS9.0000849176.79030.e3]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1650752
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact